Rhythm Pharmaceuticals, Inc. (RYTM)
RYTM moved a median of -0.11% 30 minutes after news, and +0.23% by the close. How RYTM actually reacts to news — the realized, point-in-time move the market made, measured across 477 labeled events over the last three years with zero look-ahead.
RYTM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 47% | 475 |
| 30-min | -0.11% | 46% | 476 |
| 60-min | +0.01% | 50% | 476 |
| to close | +0.23% | 55% | 475 |
| Middle 50% of RYTM reactions | -1.28% to +0.98% |
|---|---|
| Median reaction (30-min) | -0.11% |
| Measured reactions | 477 |
Half of all Rhythm Pharmaceuticals, Inc. news events land between -1.28% and +0.98% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RYTM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 38 | -0.14% | 47% | -0.52% |
| Rating reiterations | 145 | -0.02% | 49% | -0.22% |
| Price-target raises | 44 | +0.03% | 52% | +0.04% |
| Price-target cuts | 14 | +0.36% | 71% | -1.16% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how RYTM ranks against every other measured name →
That’s how RYTM usually reacts — get an email when it moves on news →Email me when RYTM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RYTM's baseline. Nothing else.
Recent RYTM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity | Press release | GlobeNewswire | -1.11% | -1.17% | |
| Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting | Press release | GlobeNewswire | +0.50% | +2.32% | |
| Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan | Press release | GlobeNewswire | -0.55% | -0.76% | |
| Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer | Press release | GlobeNewswire | -0.37% | +0.04% | |
| Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairm | Press release | GlobeNewswire | +0.95% | -0.29% | |
| Form 10-Q RHYTHM PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.80% | -0.11% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +5.07% | |
| Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.80% | -0.11% | |
| Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity | Press release | GlobeNewswire | +1.24% | +5.07% | |
| Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +1.24% | +5.07% | |
| Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 | Press release | GlobeNewswire | +1.03% | +2.32% | |
| Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity | Press release | GlobeNewswire | -0.01% | +0.61% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +1.46% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | -2.65% | -1.34% | |
| Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 | Press release | GlobeNewswire | -2.65% | -1.34% | |
| Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 | Press release | GlobeNewswire | +3.45% | -3.55% | |
| Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome | Press release | GlobeNewswire | +3.45% | -3.55% | |
| Form DEFA14A RHYTHM PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.74% | -0.06% | |
| Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026 | Press release | GlobeNewswire | -0.14% | -5.17% | |
| Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics | Press release | GlobeNewswire | -0.53% | +1.62% | |
| Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.29% | +1.16% | |
| Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology | Press release | GlobeNewswire | -0.32% | +3.44% | |
| Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference | Press release | GlobeNewswire | +0.71% | +3.81% | |
| Form 10-Q RHYTHM PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.71% | +3.81% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +3.90% | -0.20% | |
| Form DEFA14A RHYTHM PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.71% | +3.81% | |
| Form S-8 RHYTHM PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +0.71% | +3.81% | |
| Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +3.90% | -0.20% | |
| Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society | Press release | GlobeNewswire | +1.07% | +5.02% | |
| Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity | Press release | GlobeNewswire | -0.01% | -0.10% | |
| Form ARS RHYTHM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.39% | -0.83% | |
| Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +2.39% | -0.83% | |
| Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 | Press release | GlobeNewswire | +0.25% | +0.98% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +3.19% | +1.15% | |
| Rhythm Pharmaceuticals Announces Changes to Board of Directors | Press release | GlobeNewswire | +3.19% | +1.15% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -6.39% | |
| Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment | Press release | GlobeNewswire | -0.25% | -1.82% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +2.68% | -9.76% | |
| PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) | Press release | PR Newswire | +0.31% | -2.82% | |
| Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity | Press release | GlobeNewswire | +2.68% | -9.76% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | -1.80% | |
| Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial | Press release | GlobeNewswire | +1.47% | -1.80% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +4.90% | +5.29% | |
| Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity | Press release | GlobeNewswire | +4.90% | +5.29% | |
| Form 10-K RHYTHM PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.91% | -4.07% | |
| Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -6.05% | -5.02% | |
| Form S-3ASR RHYTHM PHARMACEUTICALS, | SEC filing · Form S-3ASR | SEC EDGAR | +0.91% | -4.07% | |
| Form S-8 RHYTHM PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | +0.91% | -4.07% | |
| Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update | Press release | GlobeNewswire | -6.05% | -5.02% | |
| Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 | Press release | GlobeNewswire | +1.44% | +4.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RYTM section they belong to.
Where else RYTM is measured.
RYTM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Axon Enterprise, Inc. (AXON) | 478 | -0.04% | 48% |
| RXI PHARMACEUTICALS CORP (RXII) | 477 | -1.14% | 32% |
| Ascendis Pharma A/S - Ordinary Share (ASND) | 474 | -0.08% | 48% |
| Global Cord Blood Corporation (CO) | 471 | 0.00% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rhythm Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled RYTM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 477 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of RYTM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RYTM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.